Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission

Kozlowski, Pamela A.; Aldovini, Anna

doi:10.2174/1573395514666180605092054

Cited by 26 publications

(22 citation statements)

References 386 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, TLR7/8 reinforces T cell and B cell immune responses. Vaccination with the stable forms of the virosomal HIV-1 candidate vaccine should elicit relevant protective antibodies, even if the product has been stored accidentally for a few days or weeks at 40 °C or frozen during shipment [ 57 , 81 , 82 ].…”

Section: Different Types Of Virosome-based Viral Nanovaccinesmentioning

confidence: 99%

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review

Asadi

Gholami

2021

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Vaccination is the most effective means of controlling infectious disease-related morbidity and mortality. However, due to low immunogenicity of viral antigens, nanomedicine as a new opportunity in new generation of vaccine advancement attracted researcher encouragement. Virosome is a lipidic nanomaterial emerging as FDA approved nanocarriers with promising bioinspiration and biomimetic potency against viral infections. Virosome surface modification with critical viral fusion proteins is the cornerstone of vaccine development. Surface antigens at virosomes innovatively interact with targeted receptors on host cells that evoke humoral or cellular immune responses through antibody-producing B cell and internalization by endocytosis-mediated pathways. To date, several nanovaccine based on virosome formulations have been commercialized against widespread and life-threatening infections. Recently, Great efforts were made to fabricate a virosome-based vaccine platform against a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Thus, this review provides a novel overview of the virosome based nanovaccine production, properties, and application on the viral disease, especially its importance in SARS-CoV-2 vaccine discovery.

show abstract

Section: Different Types Of Virosome-based Viral Nanovaccinesmentioning

confidence: 99%

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review

Asadi

Gholami

2021

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

show abstract

“…Hence, mucosal vaccines are superior to other vaccination strategies [ 40 ], which provides the active combat zone of defense for pathogens with mucosal initial site of entry (oral and nasal routes) [ 45 , 50 ]. Since the composition of innate cells with particular pattern recognition receptors (PRRs) is diverse in mucosal and systemic tissues, administration of the same antigen/adjuvant or the same vaccine in various routes would lead to utterly different efficiency [ 51 , 52 ]. In this regard, Pederson et al compared the intranasal and intramuscular inoculation of a candidate influenza vaccine.…”

Section: Mucosal Immunization Vs Conventional Parenteral Immunizationmentioning

confidence: 99%

The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development

Moradi‐Kalbolandi

Majidzadeh-A

Abdolvahab

et al. 2021

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing the 2019 novel coronavirus disease (COVID-19), was introduced by WHO (World Health Organization) as “pandemic” in March 2020. According to WHO, thus far (23 November 2020) 58,425,681 infected cases including 1,385,218 deaths have been reported worldwide. In order to reduce transmission and spread of this lethal virus, attempts are globally being made to develop an appropriate vaccine. Intending to neutralize pathogens at their initial entrance site, protective mucosal immunity is inevitably required. In SARS-CoV2 infection and transmission, respiratory mucosa plays a key role; hence, apparently mucosal vaccination could be a superior approach to elicit mucosal and systemic immune responses simultaneously. In this review, the advantages of mucosal vaccination to control COVID-19 infection, limitations, and outcomes of mucosal vaccines have been highlighted. Considering the gut microbiota dysregulation in COVID-19, we further provide evidences on utilization of recombinant probiotics, particularly lactic acid bacteria (LAB) as vaccine carrier. Their intrinsic immunomodulatory features, natural adjuvanticity, and feasible expression of relevant antigen in the mucosal surface make them more appealing as live cell factory. Among all available platforms, bioengineered probiotics are considered as the most affordable, most practical, and safest vaccination approach to halt this emerging virus.

show abstract

“…Indeed, distinct vaccination routes, oral, nasal, sublingual, rectal or vaginal, stimulate mucosal immunity in different locations (1,2). Furthermore, without an adequate adjuvant, vaginal immunization generally fails to stimulate robust vaginal antigen-specific antibody responses (3)(4)(5). It is only in cases where the antigen itself also acts as an adjuvant, such as cholera toxin B (6)(7)(8), or HIV-gp41 virosomes (9), that vaginal immunization allows the induction of stronger antigen-specific mucosal IgG and IgA responses than parenteral vaccination or immunization at other mucosal sites.…”

Section: Introductionmentioning

confidence: 99%

IL-7-Adjuvanted Vaginal Vaccine Elicits Strong Mucosal Immune Responses in Non-Human Primates

Logerot

Figueiredo-Morgado

Charmeteau-De-Muylder

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Mucosal immune responses are crucial in protecting against pathogens entering through mucosal surfaces. However, due to poor T-cell responsiveness upon mucosal antigenic stimulation, mucosal immunity remains difficult to obtain through vaccines and requires appropriate adjuvants. We previously demonstrated that administered systemically to healthy macaques or locally expressed in the intestinal mucosa of acutely SIV-infected macaques, interleukin-7 (IL-7) triggers chemokine expression and immune cell homing into mucosae, suggesting its important role in the development of mucosal immune responses. We therefore examined whether local delivery of recombinant glycosylated simian IL-7 (rs-IL-7gly) to the vaginal mucosa of rhesus macaques could prepare the lower female genital tract (FGT) for subsequent immunization and act as an efficient mucosal adjuvant. First, we showed that local administration of rs-IL-7gly triggers vaginal overexpression of chemokines and infiltration of mDCs, macrophages, NKs, B- and T-cells in the lamina propria while MamuLa-DR+ APCs accumulated in the epithelium. Subsequent mucosal anti-DT immunization in macaques resulted in a faster, stronger, and more persistent mucosal antibody response compared to DT-immunization alone. Indeed, we detected robust productions of DT-specific IgAs and IgGs in their vaginal secretions and identified cells secreting DT-specific IgAs in their vaginal mucosa and IgGs in draining lymph nodes. Finally, the expression of chemokines involved in the organization of tertiary lymphoid structures (TLS) was only increased in the vaginal mucosa of IL-7-adjuvanted immunized macaques. Interestingly, TLSs developed around PNAd+ high endothelial venules in their lower FGT sampled 2 weeks after the last immunization. Non-traumatic vaginal administration of rs-IL-7gly prepares the mucosa to respond to subsequent local immunization and allows the development of a strong mucosal immune response in macaques, through the chemokine-dependent recruitment of immune cells, the activation of mDCs and the formation of TLSs. The localization of DT-specific IgA+ plasma cells in the upper vaginal mucosa argues for their contribution to the production of specific immunoglobulins in the vaginal secretions. Our results highlight the potential of IL-7 as a potent mucosal adjuvant to stimulate the FGT immune system and elicit vaginal antibody responses to local immunization, which is the most promising way to confer protection against many sexually transmitted diseases.

show abstract

Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission

Cited by 26 publications

References 386 publications

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review

The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development

IL-7-Adjuvanted Vaginal Vaccine Elicits Strong Mucosal Immune Responses in Non-Human Primates

Contact Info

Product

Resources

About